Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifampicin effect on clazosentan pharmacokinetics in healthy male subjects
NL-OMON45870Active, not recruiting
- Sponsor
- Idorsia
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of clazosentan and rifampicin in cerebral vasospasm (2 arms), sponsored by Idorsia. Primary endpoint: Pharmacokinetic parameters of clazosentan. Started Jul 2018; status: active, not recruiting.
02
Drugs
clazosentanrifampicin
03
Conditions
cerebral vasospasm
Beyond the preview
Go deeper on NL-OMON45870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45870.